Page 305 - Haematologica May 2020

Non-Hodgkin Lymphoma
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
John F. Seymour,1 Robert Marcus,2 Andrew Davies,3 Eve Gallop-Evans,4 Andrew Grigg,5 Andrew Haynes,6 Michael Herold,7 Thomas Illmer,8 Herman Nilsson-Ehle,9 Martin Sökler,10 Ulrich Dünzinger,11 Tina Nielsen,12 Aino Launonen12 and Wolfgang Hiddemann13
1Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, NSW, Australia; 2Kings College Hospital, London, UK; 3Cancer Research UK Centre, University of Southampton, Southampton, UK; 4Velindre Cancer Centre, Cardiff, UK; 5Austin Hospital, Melbourne, Victoria, NSW, Australia; 6Nottingham University Hospitals NHS Trust, Nottingham, UK; 7HELIOS-Klinikum Erfurt, Germany; 8BAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany; 9Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; 10Eberhard-Karls-University Tübingen, Tübingen, Germany; 11Roche Pharma AG, Grenzach-Wyhlen, Germany; 12F. Hoffmann-La Roche Ltd., Basel, Switzerland and 13Department of Medicine III, Ludwig-Maximilians-University, München, Germany
doi:10.3324/haematol.2020.246991 ©2020 Ferrata Storti Foundation
In the article by Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W entitled ‘Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progres- sion’, published in Haematologica supplement 2019 Jun;104(6):1202-1208, there is a small data error in the Online Supplementary Table S6, the number of low-risk FLIPI patients with POD24 in the G-chemo group percentage has been mis- calculated, it should read (9.4) not (44.4).
Online Supplementary Table S6. POD24 and post-progression mortality rates, stratified by FLPI score category.
haematologica | 2020; 105(5)
1465
ERRATA CORRIGE